文献速递痛风与晶体性关节病

美国痛风与高尿酸血症当代患病率及十年趋势:NHANES 2007-2016

Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.
PubMed 文献 · Arthritis Rheumatol · 2019-04-15

高尿酸血症患病率男性20.2%、女性20.0%。2007-2016年间痛风与高尿酸血症患病率保持稳定(P for trend > 0.05)。痛风患者中仅33%接受降尿酸治疗(ULT),且该比例随时间稳定。

要点

  • 美国成人痛风患病率3.9%,男性高于女性。
  • 高尿酸血症患病率男女均约20%。
  • 仅三分之一痛风患者接受降尿酸治疗。

核心结论

  • 2007-2016年间美国痛风和高尿酸血症患病率保持稳定但数值可观,仅三分之一痛风患者接受ULT。

研究设计与样本

  • 基于美国国家健康与营养调查(NHANES)2015-2016年5467名参与者的横断面分析,并利用2007-2016年数据评估十年趋势。

主要发现

  • 男性平均血清尿酸6.0 mg/dl、女性4.8 mg/dl;高尿酸血症患病率男性20.2%、女性20.0%。
  • 2007-2016年痛风和髙尿酸血症患病率趋势无显著变化(P for trend > 0.05)。
  • 2007-2014年痛风患者ULT使用率为33%,趋势无显著变化(P for trend > 0.05)。

关键数值与推荐

  • 高尿酸血症定义为男性血清尿酸>7.0 mg/dl、女性>5.7 mg/dl。
  • 痛风定义为经健康专业人员诊断的病史。

临床怎么用

  • 提示美国痛风和高尿酸血症负担持续存在,但降尿酸治疗使用不足,需加强痛风患者的管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the current prevalence rates and decadal trends of gout and hyperuricemia in the US, as well as the prevalence of urate-lowering therapy (ULT) among gout patients, using 2007-2016 data from a nationally representative survey of American men and women (the National Health and Nutrition Examination Survey [NHANES]). METHODS: Using data from 5,467 participants in the NHANES 2015-2016, we estimated the most recent prevalence rates of gout and hyperuricemia. When the NHANES was conducted, all participants were asked about their history of gout (as diagnosed by a health professional) and medication use. Hyperuricemia was defined as having a serum urate level of >7.0 mg/dl in men and >5.7 mg/dl in women. We examined decadal trends in these estimates using data from the NHANES 2007-2016 and investigated ULT usage trends using the NHANES 2007-14 (the most recent data available to date). RESULTS: In 2015-2016, the prevalence of gout was 3.9% among adults in the US (9.2 million people), with 5.2% [5.9 million] in men and 2.7% [3.3 million] in women. Mean serum urate levels were 6.0 mg/dl in men and 4.8 mg/dl in women, and hyperuricemia prevalence rates were 20.2% and 20.0%, respectively. The prevalence rates of gout and hyperuricemia remained stable between 2007 and 2016 (P for trend > 0.05). The prevalence of ULT use among patients with gout was 33% in 2007-2014 and remained stable over time (P for trend > 0.05). CONCLUSION: In this nationally representative survey sample of adults in the US, the prevalence rates of gout and hyperuricemia remained substantial, albeit unchanged, between 2007 and 2016. Despite these rates, only one-third of gout patients were receiving ULT.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Chen-Xu M, Yokose C, Rai SK, et al. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019. PMID: 30618180. doi:10.1002/art.40807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。